应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
STOK Stoke Therapeutics, Inc.
交易中 03-20 14:32:38 EDT
34.20
+1.01
+3.04%
最高
35.08
最低
33.45
成交量
45.99万
今开
34.20
昨收
33.19
日振幅
4.93%
总市值
20.23亿
流通市值
15.03亿
总股本
5,915万
成交额
1,577万
换手率
1.05%
流通股本
4,394万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读 | 获分析师大幅上调目标价，Stoke Therapeutics盘中大涨5.39%
异动解读 · 03-20 21:45
异动解读 | 获分析师大幅上调目标价，Stoke Therapeutics盘中大涨5.39%
Stoke Therapeutics公司：前四个队列剂量递增将持续至2026年及2027年初，视安全性和耐受性评估结果而定
美股速递 · 02-11
Stoke Therapeutics公司：前四个队列剂量递增将持续至2026年及2027年初，视安全性和耐受性评估结果而定
Stoke Therapeutics宣布首位患者接受STK-002一期临床研究给药，该药物有望成为治疗常染色体显性遗传性视神经萎缩（ADOA）的疾病修正疗法
美股速递 · 02-11
Stoke Therapeutics宣布首位患者接受STK-002一期临床研究给药，该药物有望成为治疗常染色体显性遗传性视神经萎缩（ADOA）的疾病修正疗法
Stoke Therapeutics公司持续探索加快Zorevunersen研发、注册及患者用药的潜在路径
美股速递 · 01-12
Stoke Therapeutics公司持续探索加快Zorevunersen研发、注册及患者用药的潜在路径
Stoke Therapeutics公布治疗Dravet综合征药物Zorevunersen三期EMPEROR研究的入组完成与数据读取时间表更新
美股速递 · 01-12
Stoke Therapeutics公布治疗Dravet综合征药物Zorevunersen三期EMPEROR研究的入组完成与数据读取时间表更新
Stoke Therapeutics公司预计2026年第二季度完成150名患者入组，三期临床数据将于2027年中期公布
美股速递 · 01-12
Stoke Therapeutics公司预计2026年第二季度完成150名患者入组，三期临床数据将于2027年中期公布
Stoke Therapeutics, Inc.盘中异动 大幅上涨5.02%报34.19美元
市场透视 · 01-07
Stoke Therapeutics, Inc.盘中异动 大幅上涨5.02%报34.19美元
Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据
美股速递 · 2025-12-05
Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据
Stoke Therapeutics, Inc. - 截至9月30日拥有328.6百万美元现金，预计能支持运营至2028年中期
美股速递 · 2025-11-05
Stoke Therapeutics, Inc. - 截至9月30日拥有328.6百万美元现金，预计能支持运营至2028年中期
Stoke Therapeutics发布了FALCON常染色体显性视神经萎缩自然史研究的两年数据Stoke Therapeutics Releases 2-Year Data from FALCON Natural History Study in Autosomal Dominant Optic Atrophy
动脉网 · 2025-10-21
Stoke Therapeutics发布了FALCON常染色体显性视神经萎缩自然史研究的两年数据Stoke Therapeutics Releases 2-Year Data from FALCON Natural History Study in Autosomal Dominant Optic Atrophy
Stoke Therapeutics, Inc.盘中异动 股价大跌5.05%报9.22美元
市场透视 · 2025-02-19
Stoke Therapeutics, Inc.盘中异动 股价大跌5.05%报9.22美元
Chardan Capital：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由24.00美元调整至24.00美元。
金融界 · 2025-02-19
Chardan Capital：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由24.00美元调整至24.00美元。
HC Wainwright & Co.：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由35.00美元调整至47.00美元。
金融界 · 2025-02-19
HC Wainwright & Co.：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由35.00美元调整至47.00美元。
Stoke Therapeutics, Inc.盘中异动 临近午盘股价大跌5.02%
市场透视 · 2025-02-19
Stoke Therapeutics, Inc.盘中异动 临近午盘股价大跌5.02%
Stoke Therapeutics, Inc.盘中异动 股价大跌5.02%报10.78美元
市场透视 · 2025-02-11
Stoke Therapeutics, Inc.盘中异动 股价大跌5.02%报10.78美元
Stoke Therapeutics, Inc.盘中异动 下午盘股价大跌5.10%
市场透视 · 2025-02-08
Stoke Therapeutics, Inc.盘中异动 下午盘股价大跌5.10%
Stoke Therapeutics, Inc.盘中异动 早盘大幅上涨5.12%
市场透视 · 2025-02-04
Stoke Therapeutics, Inc.盘中异动 早盘大幅上涨5.12%
Stoke Therapeutics, Inc.盘中异动 下午盘股价大涨5.14%
市场透视 · 2025-01-31
Stoke Therapeutics, Inc.盘中异动 下午盘股价大涨5.14%
Stoke Therapeutics, Inc.盘中异动 急速拉升5.00%报10.29美元
市场透视 · 2025-01-23
Stoke Therapeutics, Inc.盘中异动 急速拉升5.00%报10.29美元
Stoke Therapeutics, Inc.盘中异动 股价大跌5.06%报9.01美元
市场透视 · 2025-01-16
Stoke Therapeutics, Inc.盘中异动 股价大跌5.06%报9.01美元
加载更多
公司概况
公司名称：
Stoke Therapeutics, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Stoke Therapeutics, Inc.成立于2014年6月，根据特拉华州法律注册成立。该公司是一家早期生物制药公司，开创了通过精确上调蛋白质表达来治疗严重遗传疾病的根本原因的新方法。该公司正在开发新型反义寡核苷酸（ASO）药物，靶向核糖核酸或RNA，并调节前体-信使RNA或前mRNA，在需要时以适当的特异性将蛋白质表达上调至接近正常水平。该公司利用专有技术平台，靶向增强核基因输出，或TANGO，设计ASO来上调患者个体基因对蛋白质的表达。该公司的方法旨在以高度精确、持久和可控的方式向广泛的相关组织提供疾病改善疗法，包括中枢神经系统，或中枢神经系统、眼睛、肾脏和肝脏。
发行价格：
--
{"stockData":{"symbol":"STOK","market":"US","secType":"STK","nameCN":"Stoke Therapeutics, Inc.","latestPrice":34.2,"timestamp":1774031551031,"preClose":33.19,"halted":0,"volume":459931,"delay":0,"changeRate":0.03043085266646596,"floatShares":43937800,"shares":59150790,"eps":-0.116263,"marketStatus":"交易中","change":1.01,"latestTime":"03-20 14:32:38 EDT","open":34.2,"high":35.08,"low":33.445,"amount":15768913.70809,"amplitude":0.049262,"askPrice":34.2,"askSize":51,"bidPrice":34.11,"bidSize":14,"shortable":3,"etf":0,"ttmEps":-0.116263,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"listingDate":1560916800000,"exchange":"NASDAQ","adjPreClose":33.19,"preHourTrading":{"tag":"盘前","latestPrice":34.06,"preClose":33.19,"latestTime":"09:29 EDT","volume":6544,"amount":216397.42390400002,"timestamp":1774013399999,"change":0.87,"changeRate":0.026213,"amplitude":0.043989},"postHourTrading":{"tag":"盘后","latestPrice":33,"preClose":33.19,"latestTime":"19:36 EDT","volume":22567,"amount":748903.27,"timestamp":1773963367729,"change":-0.19,"changeRate":-0.005725,"amplitude":0.015065},"volumeRatio":0.62003,"impliedVol":0.9424,"impliedVolPercentile":0.5697},"requestUrl":"/m/hq/s/STOK","defaultTab":"news","newsList":[{"id":"1189126936","title":"异动解读 | 获分析师大幅上调目标价，Stoke Therapeutics盘中大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189126936","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189126936?lang=zh_cn&edition=full","pubTime":"2026-03-20 21:45","pubTimestamp":1774014321,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics, Inc.（STOK）今日盘中股价大涨5.39%，引起了市场的关注。消息面上，根据路透报道，华尔街券商Canaccord Genuity将Stoke Therapeutics的目标价从36美元大幅上调至60美元。分析师上调目标价通常被视为对公司未来前景的积极看法，这可能是推动股价上涨的主要原因。此次目标价上调幅度显著，反映了分析师对该公司基本面的乐观预期，从而提振了投资者的信心，并在交易时段内推动了股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["STOK"],"gpt_icon":0},{"id":"1177107175","title":"Stoke Therapeutics公司：前四个队列剂量递增将持续至2026年及2027年初，视安全性和耐受性评估结果而定","url":"https://stock-news.laohu8.com/highlight/detail?id=1177107175","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177107175?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:32","pubTimestamp":1770813165,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics公司宣布，其研究项目的前四个队列剂量递增阶段将延续至2026年及2027年初。这一进程的推进将完全取决于对药物安全性和耐受性的持续评估结果。公司强调，只有在确保患者安全的前提下，才会逐步实施剂量提升方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STOK","BK4139"],"gpt_icon":0},{"id":"1107932883","title":"Stoke Therapeutics宣布首位患者接受STK-002一期临床研究给药，该药物有望成为治疗常染色体显性遗传性视神经萎缩（ADOA）的疾病修正疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1107932883","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107932883?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:31","pubTimestamp":1770813074,"startTime":"0","endTime":"0","summary":"生物技术公司Stoke Therapeutics, Inc.宣布，其在研药物STK-002的一期临床研究已完成对首位患者的给药。STK-002被开发为一种潜在的疾病修正疗法，旨在治疗常染色体显性遗传性视神经萎缩（ADOA）。该阶段的研究将评估STK-002的安全性、耐受性及药代动力学特性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STOK","BK4139"],"gpt_icon":0},{"id":"1132037514","title":"Stoke Therapeutics公司持续探索加快Zorevunersen研发、注册及患者用药的潜在路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1132037514","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132037514?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:03","pubTimestamp":1768158194,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics公司正积极研究加速其候选药物Zorevunersen从研发阶段到患者可及性的全流程优化方案。该公司致力于探索包括快速审评通道在内的多种策略，以期缩短药物上市周期，使患者能更早获得创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STOK","BK4139"],"gpt_icon":0},{"id":"1165940697","title":"Stoke Therapeutics公布治疗Dravet综合征药物Zorevunersen三期EMPEROR研究的入组完成与数据读取时间表更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1165940697","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165940697?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:01","pubTimestamp":1768158082,"startTime":"0","endTime":"0","summary":"生物制药公司Stoke Therapeutics, Inc.近日宣布，针对其治疗Dravet综合征的研究药物Zorevunersen，已对关键三期临床试验EMPEROR的研究时间表进行了重要更新。此次更新主要涉及两项核心节点：患者入组工作的预计完成时间，以及三期临床研究数据的最终读取时间。Dravet综合征是一种罕见的严重儿童期发病癫痫性脑病，Zorevunersen是该公司旨在从遗传根源上治疗该疾病的研究性疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STOK","BK4139"],"gpt_icon":0},{"id":"1178835213","title":"Stoke Therapeutics公司预计2026年第二季度完成150名患者入组，三期临床数据将于2027年中期公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1178835213","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178835213?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:01","pubTimestamp":1768158077,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics公司宣布，计划在2026年第二季度完成150名患者的入组工作。这一关键里程碑将为后续临床研究奠定基础。公司预计，三期临床试验的数据结果将于2027年中期正式公布。这一时间表的推进，标志着公司在相关治疗领域的研发工作取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STOK","BK4139"],"gpt_icon":0},{"id":"2601084320","title":"Stoke Therapeutics, Inc.盘中异动 大幅上涨5.02%报34.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601084320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601084320?lang=zh_cn&edition=full","pubTime":"2026-01-07 00:42","pubTimestamp":1767717730,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日00时42分，Stoke Therapeutics, Inc.股票出现波动，股价大幅上涨5.02%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。其相关个股中，Alumis Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 、Seastar Medical Holding Corp C/Wts 28/10/2027 涨幅较大，Pmgc Holdings Inc.、Cyclerion Therapeutics, Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为2156.83%、1600.39%、233.97%，振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Alumis Inc.，振幅分别为294.74%、161.40%、71.00%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 是一家致力于利用 RNA 医药开发来恢复蛋白质表达的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107004211a4a42806&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107004211a4a42806&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","STOK","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"1149660254","title":"Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1149660254","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149660254?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:00","pubTimestamp":1764943218,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0109394709.USD","BIIB","IE00B19Z9Z06.USD","LU0889565916.HKD","IE00B894F039.SGD","STOK","BK4533","LU0234570918.USD","BK4588","LU0320765992.SGD","IE00B19Z9P08.USD","BK4532","BK4585"],"gpt_icon":0},{"id":"1152016646","title":"Stoke Therapeutics, Inc. - 截至9月30日拥有328.6百万美元现金，预计能支持运营至2028年中期","url":"https://stock-news.laohu8.com/highlight/detail?id=1152016646","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152016646?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:05","pubTimestamp":1762290308,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics, Inc. - 截至9月30日拥有328.6百万美元现金，预计能支持运营至2028年中期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STOK"],"gpt_icon":0},{"id":"2577809746","title":"Stoke Therapeutics发布了FALCON常染色体显性视神经萎缩自然史研究的两年数据Stoke Therapeutics Releases 2-Year Data from FALCON Natural History Study in Autosomal Dominant Optic Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2577809746","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577809746?lang=zh_cn&edition=full","pubTime":"2025-10-21 21:15","pubTimestamp":1761052500,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics Releases 2-Year Data from FALCON Natural History Study in Autosomal Dominant Optic AtrophyStoke Therapeutics发布FALCON常染色体显性视神经萎缩自然史研究的两年数据October 21, 20252025年10月21日Stoke Therapeutics has announced two-year results from its FALCON study, the largest prospective natural history study to date in individuals living with autosomal dominant optic atrophy , a rare, inherited eye disease that causes progressive and irreversible vision loss, typically beginning in childhood..Stoke Therapeutics 宣布了其FALCON研究的两年结果，这是迄今为止针对常染色体显性视神经萎缩患者的规模最大的前瞻性自然史研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021211902a46c759f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021211902a46c759f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","STOK","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2512481552","title":"Stoke Therapeutics, Inc.盘中异动 股价大跌5.05%报9.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512481552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512481552?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:49","pubTimestamp":1739980170,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时49分，Stoke Therapeutics, Inc.股票出现波动，股价大幅跳水5.05%。截至发稿，该股报9.22美元/股，成交量25.0385万股，换手率0.47%，振幅6.75%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.63%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219234931abd50f55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219234931abd50f55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","STOK","LENZ"],"gpt_icon":0},{"id":"2512031081","title":"Chardan Capital：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由24.00美元调整至24.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512031081","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512031081?lang=zh_cn&edition=full","pubTime":"2025-02-19 19:41","pubTimestamp":1739965272,"startTime":"0","endTime":"0","summary":"Chardan Capital：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由24.00美元调整至24.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19194148264816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["STOK","LENZ"],"gpt_icon":0},{"id":"2512193780","title":"HC Wainwright & Co.：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由35.00美元调整至47.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512193780","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512193780?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:21","pubTimestamp":1739902892,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由35.00美元调整至47.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19022148243309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["STOK","LENZ"],"gpt_icon":0},{"id":"2512167390","title":"Stoke Therapeutics, Inc.盘中异动 临近午盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512167390","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512167390?lang=zh_cn&edition=full","pubTime":"2025-02-19 00:44","pubTimestamp":1739897053,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日00时44分，Stoke Therapeutics, Inc.股票出现异动，股价快速下跌5.02%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。其相关个股中，Estrella Immunopharma Inc C/Wts 29/09/2028、Ocean Biomedical Inc C/Wts 14/02/2028 、Solid Biosciences Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为404.41%、180.64%、152.15%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219004413abd3cb9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219004413abd3cb9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["STOK","BK4139","LENZ"],"gpt_icon":0},{"id":"2510860954","title":"Stoke Therapeutics, Inc.盘中异动 股价大跌5.02%报10.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510860954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510860954?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:06","pubTimestamp":1739207178,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时06分，Stoke Therapeutics, Inc.股票出现波动，股价大幅下挫5.02%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Biodexa Pharmaceuticals Plc、Dominari Holdings Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为2924.99%、1588.47%、1149.27%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Abpro Holdings Inc C/Wts 12/11/2029 、Ocean Biomedical, Inc.，振幅分别为99.86%、87.80%、85.48%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211010619a240c260&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211010619a240c260&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","STOK","BK4139"],"gpt_icon":0},{"id":"2509278127","title":"Stoke Therapeutics, Inc.盘中异动 下午盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509278127","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509278127?lang=zh_cn&edition=full","pubTime":"2025-02-08 02:24","pubTimestamp":1738952640,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日02时24分，Stoke Therapeutics, Inc.股票出现异动，股价急速下跌5.10%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.56%。其相关个股中，Conduit Pharmaceuticals Inc.、Sionna Therapeutics, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为7668.46%、173.84%、123.00%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为130.43%、93.55%、53.38%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208022401abc65c16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208022401abc65c16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","STOK"],"gpt_icon":0},{"id":"2508310463","title":"Stoke Therapeutics, Inc.盘中异动 早盘大幅上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508310463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508310463?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:06","pubTimestamp":1738681573,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时06分，Stoke Therapeutics, Inc.股票出现异动，股价急速上涨5.12%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.00%。其相关个股中，Azitra Inc、Evaxion Biotech As、Regulus Therapeutics Inc.涨幅较大，Azitra Inc、Evaxion Biotech As、Enveric Biosciences, Inc.较为活跃，换手率分别为1414.21%、852.16%、218.57%，振幅较大的相关个股有Azitra Inc、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Briacell Therapeutics Corp C/Wts 24/02/2025，振幅分别为60.25%、49.88%、40.00%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502042306139617dd69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502042306139617dd69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","STOK","LENZ"],"gpt_icon":0},{"id":"2507672598","title":"Stoke Therapeutics, Inc.盘中异动 下午盘股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507672598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507672598?lang=zh_cn&edition=full","pubTime":"2025-01-31 03:12","pubTimestamp":1738264336,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日03时12分，Stoke Therapeutics, Inc.股票出现异动，股价快速上涨5.14%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Immatics N V C/Wts 01/07/2025 涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1785.55%、301.33%、242.74%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 、Alterity Therapeutics Limited，振幅分别为65.98%、64.10%、61.86%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501310312169876cfdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501310312169876cfdb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","STOK","LENZ"],"gpt_icon":0},{"id":"2505771354","title":"Stoke Therapeutics, Inc.盘中异动 急速拉升5.00%报10.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505771354","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505771354?lang=zh_cn&edition=full","pubTime":"2025-01-23 01:54","pubTimestamp":1737568489,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日01时54分，Stoke Therapeutics, Inc.股票出现波动，股价急速拉升5.00%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Nutriband Inc C/Wts 、Immunoprecise Antibodies Ltd.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Immunoprecise Antibodies Ltd.、Hepion Pharmaceuticals, Inc.、Cardio Diagnostics Holdings Inc.较为活跃，换手率分别为977.42%、307.75%、76.95%，振幅较大的相关个股有Immunoprecise Antibodies Ltd.、Immatics N V C/Wts 01/07/2025 、Nutriband Inc C/Wts ，振幅分别为60.53%、53.51%、50.39%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123015450960d201f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123015450960d201f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","STOK","LENZ"],"gpt_icon":0},{"id":"2503916051","title":"Stoke Therapeutics, Inc.盘中异动 股价大跌5.06%报9.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503916051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503916051?lang=zh_cn&edition=full","pubTime":"2025-01-16 23:03","pubTimestamp":1737039839,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日23时03分，Stoke Therapeutics, Inc.股票出现波动，股价大幅下挫5.06%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.94%。其相关个股中，Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Psyence Biomedical Ltd C/Wts 25/01/2029、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 涨幅较大，Aditxt, Inc.、Palisade Bio, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1650.68%、359.28%、232.75%，振幅较大的相关个股有Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Aditxt, Inc.、Channel Therapeutics Corporation，振幅分别为131.33%、61.60%、55.47%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011623040098689301&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011623040098689301&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","STOK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.stoketherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0902},{"period":"1month","weight":0.0675},{"period":"3month","weight":0.0385},{"period":"6month","weight":0.4493},{"period":"1year","weight":3.0182},{"period":"ytd","weight":0.0457}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Stoke Therapeutics, Inc.成立于2014年6月，根据特拉华州法律注册成立。该公司是一家早期生物制药公司，开创了通过精确上调蛋白质表达来治疗严重遗传疾病的根本原因的新方法。该公司正在开发新型反义寡核苷酸（ASO）药物，靶向核糖核酸或RNA，并调节前体-信使RNA或前mRNA，在需要时以适当的特异性将蛋白质表达上调至接近正常水平。该公司利用专有技术平台，靶向增强核基因输出，或TANGO，设计ASO来上调患者个体基因对蛋白质的表达。该公司的方法旨在以高度精确、持久和可控的方式向广泛的相关组织提供疾病改善疗法，包括中枢神经系统，或中枢神经系统、眼睛、肾脏和肝脏。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.03437},{"month":2,"riseRate":0.428571,"avgChangeRate":0.03862},{"month":3,"riseRate":0.285714,"avgChangeRate":0.013308},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.035354},{"month":5,"riseRate":0.666667,"avgChangeRate":0.157425},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022668},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.037597},{"month":8,"riseRate":0.571429,"avgChangeRate":0.139168},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.103771},{"month":10,"riseRate":0.714286,"avgChangeRate":0.110002},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.025248},{"month":12,"riseRate":0.714286,"avgChangeRate":0.122564}],"exchange":"NASDAQ","name":"Stoke Therapeutics, Inc.","nameEN":"Stoke Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Stoke Therapeutics, Inc.(STOK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Stoke Therapeutics, Inc.(STOK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Stoke Therapeutics, Inc.,STOK,Stoke Therapeutics, Inc.股票,Stoke Therapeutics, Inc.股票老虎,Stoke Therapeutics, Inc.股票老虎国际,Stoke Therapeutics, Inc.行情,Stoke Therapeutics, Inc.股票行情,Stoke Therapeutics, Inc.股价,Stoke Therapeutics, Inc.股市,Stoke Therapeutics, Inc.股票价格,Stoke Therapeutics, Inc.股票交易,Stoke Therapeutics, Inc.股票购买,Stoke Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Stoke Therapeutics, Inc.(STOK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Stoke Therapeutics, Inc.(STOK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}